Patient with psoriasis and metabolic syndrome. Thanks to the topical application of Enstilar foam we avoided to immediately need of systemic treatment in psoriasis
Abstract
Psoriasis is chronic inflammatory dermatoses affecting about 2-3% of mid european population. Local therapy can effectively treat mild to moderate psoriasis, in severe forms we approach to systemic treatment.
In this case study we follow a patient with severe form of psoriasis indicated to systemic treatment. It was not possible to start available conventional systemic treatment due to for unsatisfactory values of serum lipids, liver tests and uncorrected arterial hypertension.
Therefore, we started treat with the combination of calcipotriol and betamethasone dipropionate (Enstilar cutaneous foam), with a satisfactory therapeutic effect, that also declare a decrease in PASI from 7.8 to 2 after one month of treatment. Thus, we were able to avoid of immediately need of systemic treatment, which selection will by difficult due to metabolic syndrome.
This case report also demonstrates the need to prescribe a sufficient amount of the drug to cover the time until next appointment with the doctor.